These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 22790633)
1. [It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy]. Takamatsu Y Rinsho Ketsueki; 2012 Jun; 53(6):587-93. PubMed ID: 22790633 [No Abstract] [Full Text] [Related]
3. [Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients]. Mellstedt H; Gimsing P; Waage A Lakartidningen; 2011 Oct 19-25; 108(42):2090-4. PubMed ID: 22165535 [No Abstract] [Full Text] [Related]
4. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778 [TBL] [Abstract][Full Text] [Related]
5. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide. Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555 [TBL] [Abstract][Full Text] [Related]
6. Advances in the treatment of MDS, multiple myeloma, and CLL. Snively A ONS Connect; 2007; 22(8 Suppl):55-6. PubMed ID: 17824566 [No Abstract] [Full Text] [Related]
7. Treatment paradigms for the newly diagnosed patient with multiple myeloma. Greipp P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097 [TBL] [Abstract][Full Text] [Related]
8. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience. Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080 [TBL] [Abstract][Full Text] [Related]
9. Clinical management of myeloma--state of the art. Harousseau JL Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182 [TBL] [Abstract][Full Text] [Related]
10. Novel agents in myeloma: an exciting saga. Mark T; Niesvizky R; Coleman M Cancer; 2009 Jan; 115(2):236-42. PubMed ID: 19025986 [No Abstract] [Full Text] [Related]
12. Management of older patients with multiple myeloma. Gay F; Palumbo A Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387 [TBL] [Abstract][Full Text] [Related]
13. Bortezomib increases survival of patients with relapsed multiple myeloma. Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682 [No Abstract] [Full Text] [Related]
14. [Supportive care in multiple myeloma for continuing anti-myeloma therapies]. Shibayama H Rinsho Ketsueki; 2014 Oct; 55(10):1999-2004. PubMed ID: 25297765 [No Abstract] [Full Text] [Related]
15. Lenalidomide efficacy in bortezomib-resistant myeloma. Gozzetti A; Crupi R; Defina M; Bocchia M Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907 [No Abstract] [Full Text] [Related]
16. Diagnosis and the current trends in multiple myeloma therapy. DmoszyĆska A Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817 [TBL] [Abstract][Full Text] [Related]
18. Novel agents in the frontline management of multiple myeloma. Loong HH Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474 [TBL] [Abstract][Full Text] [Related]
19. Current status of new drugs for the treatment of patients with multiple myeloma. Kenealy M; Prince HM Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741 [TBL] [Abstract][Full Text] [Related]
20. Drugs: More shots on target. Appel A Nature; 2011 Dec; 480(7377):S40-2. PubMed ID: 22169800 [No Abstract] [Full Text] [Related] [Next] [New Search]